Evidence shows that there is a rapid increase in the production of markers of oxidative damage immediately following acute stroke and that endogenous antioxidant defences are rapidly depleted, thus permitting further tissue damage. Several studies point to an antioxidant effect of B-group vitamins and a pro-oxidant effect of elevated plasma tHcy (total homocysteine). In the present study, we assessed whether supplementary B-group vitamins during this critical period will enhance antioxidant capacity and mitigate oxidative damage. Forty-eight patients with acute ischaemic stroke within 12 h of symptom onset were assigned to receive daily oral supplements of B-group vitamins comprising 5 mg of folate, 5 mg of vitamin B 2 , 50 mg of vitamin B 6 and 0.4 mg of vitamin B 12 (n = 24) or no supplements (n = 24) for 14 days. The treatment group and controls were matched for stroke subtype and age. Blood samples were obtained before intervention and also at 7 and 14 days post-recruitment for measurement of the following biomarkers: red cell folate (whole blood folate corrected with haematocrit), erythrocyte glutathione reductase activity coefficient (EGRAC; measure of vitamin B 2 status), plasma pyridoxal phosphate (vitamin B 6 status), plasma vitamin B 12 , plasma α-tocopherol, plasma ascorbic acid, plasma TAOC (total antioxidant capacity), plasma MDA (malondialdehyde), plasma tHcy and CRP (C-reactive protein). Supplementation for 14 days with B-group vitamins significantly increased the plasma concentrations of pyridoxal phosphate and red blood cell folate and improved a measure of B 2 status compared with the control group (P < 0.05). Plasma tHcy decreased in both groups albeit less in the control group, but differences in cumulative changes were not significant. There was, however, a decrease in plasma MDA concentration in the treatment group, in contrast with the increase seen in the control group and these differences were significant (P = 0.05). CRP concentration, a marker of tissue inflammation, was significantly lower in the treatment group compared with controls (P < 0.05). In conclusion, B-group vitamin supplementation immediately post-infarct may have antioxidant and anti-inflammatory effects in stroke disease independent of a homocysteine-lowering effect.
INTRODUCTION
Stroke is the third most common cause of death in most Western populations after coronary heart disease and cancer [1] . The majority of strokes are not fatal, and the major burden is long-term disability. It is therefore the most important single cause of severe disability among Western people living in their own homes [2] . Stroke in the developing world is less well documented. A statement from the Asia-Pacific Consensus Forum on Stroke Management predicts that 'In the next 30 years or so the burden of stroke will grow most in developing countries rather than in the developed world' [3] .
There is strong indirect evidence that free radical production is an important mechanism of brain injury after exposure to ischaemia and reperfusion [4] . Lipid peroxidation with accumulation of both conjugated dienes and thiobarbiturate-reactive material is consistently found when cerebral ischaemia is followed by reperfusion [4] . Recent studies in humans have reported an association between plasma concentration of antioxidants, markers of oxidative damage and early clinical outcome after acute ischaemic stroke [5, 6] .
Elevated levels of plasma tHcy (total homocysteine) and deficiencies in folate or vitamin B 6 or B 12 cofactors have been found in atherosclerotic patients, including strokes [7] . Several studies suggest that tHcy may have a pro-oxidant effect and a role in the production of reactive oxygen species that results in oxidative damage to arterial endothelial cells [8, 9] . Through cofactor roles in homocysteine metabolism, increased intakes of B-vitamins have homocysteine-lowering effects [9] . The effect is strongest for folate, but vitamins B 6 , B 12 and B 2 have all been shown to be independently predictive of plasma homocysteine. There is also recent evidence suggesting an acute antioxidant effect of folate independent of its effect on homocysteine [10, 11] . Riboflavin may also have protective effects independent of homocysteine-lowering; this vitamin may protect tissues from ischaemia/reperfusion injury, probably through an antioxidant effect [12] .
We hypothesize that there is a rapid increase in the production of markers of oxidative damage following acute stroke due to the reperfusion event following ischaemia. Supplementary B-group vitamins during this critical period will enhance antioxidant capacity and mitigate oxidative damage. The aim of the present study was, therefore, to test the effect of supplementary B-group vitamins during this critical period on plasma markers of antioxidant capacity, oxidative damage and plasma tHcy concentration.
METHODS

Subjects
For a 12-month period, all patients admitted to a University Teaching Hospital with a diagnosis of ischaemic stroke according to the World Health Organization criteria were identified prospectively. The study was approved by the Local Health Research Ethics Committee. After providing informed written consent, 48 patients with acute ischaemic stroke admitted within 12 h of symptom onset (excluding those with cerebral or subarachnoid haemorrhage on CT head scan) were randomly assigned to receive oral supplements of B-group vitamins comprising 5 mg of folate, 5 mg of vitamin B 2 , 50 mg of vitamin B 6 and 0.4 mg of vitamin B 12 (n = 24) daily, or no supplement (n = 24), for 14 days. All patients, however, received standard medical treatment for acute stroke. No subject received thrombolytic therapy. Stroke patients with active gastrointestinal disease, severe medical or psychiatric illness, serum creatinine concentration > 150 µmol/l, history of gout or acute renal failure, supplemental vitamins or inability or refusal to give consent were excluded. The treatment group and controls were matched for age and stroke subtype. The classification of stroke subtypes was based on clinically identifiable subtypes of cerebral infarction as described by Bamford et al. [13] . This classification has important prognostic implications and is useful for planning stroke treatment trials. The classification is as follows: large anterior circulation infarcts with both cortical and subcortical involvement [TACI (total anterior circulation infarcts)]; more restricted and predominantly cortical infarcts [PACI (partial anterior circulation infarcts)]; infarcts associated with the vertebro-basilar arterial territory [POCI (posterior circulation infarcts)]; and infarcts confined to the territory of the deep perforating arteries [LACI (lacunar infarcts)].
Protocol
Non-fasting venous blood was obtained before treatment (within 12 h of stroke onset) and at day 7 and day 14. Blood was collected in appropriate tubes, the haematocrit measured and an aliquot of whole blood stored at − 70
• C with ascorbic acid for the measurement of red blood cell folate. Following separation from red blood cells, plasma was stored, with stabilizer where appropriate, at − 70
• C for analysis within 12 weeks. Red blood cells were washed, haemolysed and stored at − 70
• C for the later measurement of vitamin B 2 status. All analyses were performed blind to the identity of the sample. Plasma B 12 was measured by competitive immunoassay using direct chemiluminescence on an ADVIA Centaur system (kit reference 09544818; Bayer, Newbury, Berkshire, U.K.). The inter-batch CV (coefficient of variation) was 7.0 %. The automated Ion Capture Assay system (IMX folate assay; Abbott Laboratories, Abbott Park, IL, U.S.A.) was utilized to determine the total folate concentration of whole blood, and had an inter-batch CV of 6.1 %. Simultaneously measured haematocrit values were then used to calculate red cell folate concentrations. Riboflavin status was assessed as the EGRAC (erythrocyte glutathione reductase activity coefficient), using the Cobas BioAutoanalyser (Roche Diagnostics, Indianapolis, IN, U.S.A.) [14] , with an inter-batch CV of 3.4 %. Ratios above 1.4 were considered to reflect biochemical deficiency of riboflavin. Pyridoxine (vitamin B 6 ) was measured as plasma pyridoxal phosphate by HPLC [15] ; this assay had an inter-batch CV of 8.0 %. Plasma tHcy was determined by an automated fluorescence polarization immunoassay (IMX Hcy assay; Abbot Laboratories) with an inter-batch CV of 5.4 %. Plasma α-tocopherol was measured by HPLC [16] , and plasma total ascorbic acid was by a fluorescence assay automated for the Cobas BioAutoanalyser [17] , giving inter-batch CVs of 4.3 and 9.0 % respectively. TAOC (total antioxidant capacity) was measured as the ability of plasma to inhibit free-radical-induced oxidation in an assay automated for the Cobas BioAutoanalyser, with an inter-batch CV of 5.0 % [18] . Serum total cholesterol concentrations, measured by a cholesterol oxidase assay using the Synchron LX System (kit reference 467825; Beckman, Fullerton, CA, U.S.A.), were used to adjust α-tocopherol values. The inter-batch CV of this assay was 6.0 %. Plasma MDA (malondialdehyde), a marker of lipid peroxidation, was also measured by HPLC using fluorescence detection [19] , and this had an inter-batch CV of 9.0 %. CRP (C-reactive protein) concentration, a marker of acute inflammation in stroke [20] and other illnesses (normal range, < 6 mg/l), was measured by a modified latex-enhanced immuno-turbidimetric assay (Synchron LX System; kit reference 465131; Beckman). Plasma uric acid concentration was measured by an enzymic uricase fluorescence method (normal range, 160-400 µmol/l) on the Synchron LX System (kit reference 442785; Beckman). The inter-batch CVs for these assays were 6.5 % and 5.0 % respectively.
All patients had demographic and medical data collected at baseline, including history of hypertension, smoking, alcohol and drug intake, diabetes mellitus and cardiovascular diseases. Disability at baseline was assessed using the Barthel score on a 100-point scale [21] . The Barthel scores 10 functions on a scale 0 (fully dependent) to 100 (independent).
Allocation of treatment
The method of minimization [22] is an accepted form of randomization and was chosen because it minimizes any differences and provides treatment groups very similar for major prognostic variables. The effect of this procedure was that the groups were similar with regard to the chosen variables of interest. In this trial, clinical stroke subtype (TACI, PACI, LACI and POCI) and age (< 75 and 75 years) were used for minimization.
Sample size calculation
A previous study [23] has shown that daily supplementation with B-group vitamins (5 mg of folate, 50 mg of vitamin B 6 and 0.4 mg of vitamin B 12 ) to patients with recurrent venous thrombosis (19 on supplements compared with 15 on placebo) reduced plasma tHcy concentrations by up to 33 %. A sample size of 48 ischaemic stroke patients (24 treatment group + 24 controls) would therefore allow the detection of a 30 % difference between groups in plasma tHcy with 80 % power and type 1 error probability of 0.05.
Data analysis
Statistical analyses were performed with SPSS software, version 11.0 (SPSS Inc., Chicago, IL, U.S.A.). Descriptive tests (median and inter-quartile range) were used to describe the baseline characteristics of the subjects. Kruskal-Wallis and Mann-Whitney U tests were used to test between-group differences where appropriate. The Friedman test was used to test within-group differences. Forward stepwise multiple regression analysis was performed to determine the predictive importance of baseline variables (age, stroke subtype, drugs, chronic disease and CRP) for plasma TAOC, MDA and tHcy. Adjusted and change in R 2 values were then used to determine the extent to which the TAOC, MDA and tHcy concentrations could be explained by individual antioxidants (vitamin C, vitamin E and uric acid) and B-group vitamins, but also other clinical variables included in the model. Table 1 shows baseline characteristics of the treatment and control groups on entry into the study. The two groups were comparable with respect to clinical stroke subtype, chronic disease, drug and alcohol intake and time between stroke onset and randomization. Although there were some differences between the two groups in age, rate of atrial fibrillation, disability, blood glucose and serum creatinine, these differences did not reach statistical significance, except for blood glucose (P < 0.05). Vitamin supplements were prescribed in the drug cards of the patients, and compliance for surviving patients was 100 % with no treatment failure or withdrawal.
RESULTS
The concentrations of plasma vitamins B 6 and B 12 , redcell folate and EGRAC (vitamin B 2 ) values are shown in Table 2 . Supplementation of B-group vitamin for 14 days significantly increased concentrations of plasma vitamin B 6 and red cell folate and reduced EGRAC (inversely associated with riboflavin status) in the intervention group compared with controls. Concentrations of plasma vitamin B 12 increased significantly in both groups over 2 weeks (P < 0.05 for within-group differences), but there was no significant difference between groups. Table 3 shows plasma concentrations of ascorbic acid, α-tocopherol, TAOC and MDA during the study period. Within-group and between-group differences in plasma ascorbic acid, α-tocopherol and TAOC were not significant. Although plasma TAOC concentrations decreased in both groups, albeit less so in the treatment group over the study period, cumulative differences between the two groups were not statistically significant. However, the reduction in plasma MDA concentration seen in the treatment group was in contrast with the increase seen in the control group and these different responses were significant. Plasma tHcy concentrations decreased more in the treatment group than the controls, but difference in cumulative changes between the two groups was not significant (Table 4) . In a multivariate analysis, plasma uric acid and red cell folate explained most of the variance in TAOC during the study period. Of the other variables included Table 5) . Most of the variance in MDA was explained by age at baseline and α-tocopherol at day 7, but tHcy showed significant positive correlation with MDA at baseline and day 14 (Table 6) .
We also analysed the effects of B-group vitamins, age, stroke subtype, tissue inflammation (CRP), drugs and alcohol on plasma tHcy during the study period using a multivariate model. Folate and age were significant predictors of tHcy during the study period (Table 7) . Figure 1 shows the CRP profile over a period of 3 months following the stroke. CRP concentrations were significantly lower in the treatment group compared with controls (P < 0.05). There were no statistically significant differences in the rate of infective complications (pneumonia, urinary tract infection and septicaemia) or reinfarction between the treatment group and controls during the first 2 weeks post-randomization [two (8 %) and no patients in the treatment group had infective complications during the first and second weeks postrandomization respectively, compared with three (13 %) and one (4 %) in the control group; two [8 %] stroke patients in the treatment group had recurrent cerebral infarction compared with two (8 %) controls].
DISCUSSION
Supplementation with B-group vitamins within 12 h post-infarct after ischaemic stroke reduced lipid peroxidation products (MDA) after 2 weeks. This occurred in association with a predicted increase in the plasma concentrations of certain B vitamins. Although tHcy decreased more in the treatment group compared with controls, overall there was no significant difference between the two groups. Plasma CRP, a marker of tissue inflammation, was also lower over 90 days in those subjects who received B-group vitamin supplements for 14 days compared with controls. Plasma TAOC concentrations decreased in both groups and cumulative differences between the two groups were not statistically significant. Plasma TAOC was significantly accounted for by serum uric acid and red cell folate status. Most of Many recent studies have reported an association between plasma tHcy concentrations and risk of stroke independent of other prognostic indicators [7] . Mechanisms whereby elevated plasma tHcy increases risk of stroke are not fully understood, but several studies point to a pro-oxidant effect. High homocysteine levels may lead to endothelial damage, affect platelet function and coagulation factors, and promote LDL (low-density lipoprotein) oxidation [8, 9, 24] . Hyperhomocysteinaemia has been suggested to play a role in the production of reactive oxygen species, resulting in oxidative damage to arterial endothelial cells [9, 25] . The homocysteine-lowering activity of B-group vitamins may therefore be viewed as potentially antioxidant in nature. However, folate can evidently behave as a free-radical scavenger, which might explain reported beneficial effects of high-dose folate on the vasculature [26] . Nakano et al. [10] have shown recently that folate has a direct protective antioxidant effect on LDL oxidation in vitro, and others have shown protective effects on the endothelium that appear to be independent of homocysteine-lowering [11] .
Elevated plasma CRP concentration during the acute phase or recovery in stroke is independently predictive of poor long-term outcome [27, 28] . We found a significant Values [medians (inter-quartile range)] for the CRP levels in the treatment and control group are: treatment group (n = 24), 6 (6-12) on day 0, 7 (6-14) on day 7, 6 (6-12) on day 14 and 6 (6-6) on day 90; control group (n = 24), 6 (6-9) on day 0, 23 (7-108) on day 7, 18 (6-38) on day 14 and 14 (6-72) on day 90. P < 0.05 for the difference in cumulative change between the groups.
difference in the CRP concentrations between the stroke patients who received B-group vitamins and the matched controls within 3 months following the stroke. This difference could not be explained by the difference in secondary complications such as infections and re-infarction between the two groups. Although CRP has not been directly linked to oxidative stress, recent reports suggest that high CRP concentrations may reflect the degree of stroke severity correlating with the degree of inflammation directly consequent to cerebral infarction, underlying unstable atherosclerotic lesions and/or secondary complications of stroke at the time of sampling [20] .
Could the lower CRP concentrations in the treatment group be due to an anti-inflammatory/neuroprotective effect of the B-group vitamins as a result of their antioxidant effect, or could it simply be explained by stroke severity and secondary complications? Although we have adjusted for some important prognostic variables such as the nature of cerebral infarction and secondary complications in our study, it is impossible to exclude other sub-clinical causes for the differences in CRP concentrations. However, Friso et al. [29] have shown in a population-based study that low plasma pyridoxal 5 -phosphate status, the active form of vitamin B 6 , was associated with higher CRP concentrations independently of homocysteine. Supplementation induced small, but significant, changes in certain B-group vitamins, markers of oxidative damage and tissue inflammation. Although our sample size was small and larger studies with clinical end points need to be undertaken to determine the biological and functional relevance of these changes, recent observational studies in humans have reported an association between plasma concentration of antioxidants, markers of oxidative damage and early functional and clinical outcome after acute ischaemic stroke [5, 6] . We are not aware of any other studies showing an independent effect of the other B-group vitamins used in the present study on plasma CRP. The possible anti-inflammatory and neuroprotective effect of B-group vitamins immediately post-infarct will need further exploration.
We have also found that uric acid explained most of the variance in TAOC during the study period. In a recent study [30] , we have reported reduced plasma concentrations of TAOC in patients with ischaemic stroke compared with non-stroke controls and that TAOC was strongly correlated with serum uric acid concentrations. Cerebral ischaemia and reperfusion is accompanied by increased purine metabolism and uric acid formation [4] ; however, the formation of uric acid from hypoxanthine, through the activity of xanthine oxidase, is itself associated with the production of the oxygen-centred radical superoxide. Some investigators have shown that blocking the activity of this enzyme may improve recovery from cerebral ischaemia and reperfusion [31] . Further work is needed to explore the physiological roles of uric acid following acute ischaemic stroke.
B-group vitamins used in the present study did not decrease plasma tHcy concentrations as evident from other studies, although we are not aware of any trial that has yet measured the effectiveness of B-group vitamins in lowering tHcy immediately after acute ischaemic stroke. Woodside et al. [32] , for example, carried out a doubleblind, randomized, factorial-design, controlled trial in which they supplemented 22 men for 8 weeks with B-group vitamins (1 mg of folate, 7.2 mg of vitamin B 6 and 0.02 mg of vitamin B 12 ). They found that supplementation with the B-group vitamins significantly reduced tHcy concentration by 27.9 % in the men with mildly elevated homocysteine. In our present study, the lack of change in tHcy in the supplemented group may have been due to the shorter period of supplementation. However, our main objective in the present study was to evaluate the effect of B-group vitamins on markers of antioxidant capacity and oxidative damage immediately post-infarct after acute ischaemic stroke.
Intervention produced a very small difference in vitamin B 12 concentrations with a similar increase seen in the control group. This lack of difference may have been due to the relatively modest dose of vitamin B 12 used, length of treatment, tissue inflammation or differences in rate of absorption between subjects.
In conclusion, we have demonstrated that supplementation with B-group vitamins within 12 h post-infarct after acute stroke may have antioxidant and anti-inflammatory effects independent of their homocysteinelowering effect. Although there are many ongoing prospective controlled intervention trials using folate, vitamin B 12 and vitamin B 6 as homocysteine-lowering agents in vascular disease, there is a need to explore further the potential antioxidant effects of B-group vitamins and to test the potential synergistic interactions between B-group vitamins and conventional antioxidants in acute stroke patients immediately post-infarct.
